JP2014512402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512402A5 JP2014512402A5 JP2014506850A JP2014506850A JP2014512402A5 JP 2014512402 A5 JP2014512402 A5 JP 2014512402A5 JP 2014506850 A JP2014506850 A JP 2014506850A JP 2014506850 A JP2014506850 A JP 2014506850A JP 2014512402 A5 JP2014512402 A5 JP 2014512402A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- melphalan
- pharmaceutical preparation
- excipient
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YQZNKYXGZSVEHI-VXKWHMMOSA-N ethyl (2s)-2-[[(2s)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-3-(4-fluorophenyl)propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(=CC=1)N(CCCl)CCCl)C1=CC=C(F)C=C1 YQZNKYXGZSVEHI-VXKWHMMOSA-N 0.000 claims description 47
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 39
- 229950009924 melphalan flufenamide Drugs 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 35
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 11
- 239000005720 sucrose Substances 0.000 claims description 11
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 10
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 10
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 10
- 229960001924 melphalan Drugs 0.000 claims 10
- QAZLUNIWYYOJPC-UHFFFAOYSA-M sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 claims 9
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 claims 4
- 125000000185 sucrose group Chemical group 0.000 claims 2
- 125000000647 trehalose group Chemical group 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 9
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
- 229920000053 polysorbate 80 Polymers 0.000 description 9
- 229940068968 polysorbate 80 Drugs 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 7
- 239000008389 polyethoxylated castor oil Substances 0.000 description 7
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 7
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 6
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 6
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical group OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 6
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1150371 | 2011-04-28 | ||
| SE1150371-1 | 2011-04-28 | ||
| US201161535126P | 2011-09-15 | 2011-09-15 | |
| US61/535,126 | 2011-09-15 | ||
| PCT/EP2012/057577 WO2012146625A1 (en) | 2011-04-28 | 2012-04-25 | Lyophilized preparation of cytotoxic dipeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512402A JP2014512402A (ja) | 2014-05-22 |
| JP2014512402A5 true JP2014512402A5 (OSRAM) | 2015-06-18 |
| JP6042412B2 JP6042412B2 (ja) | 2016-12-14 |
Family
ID=47071620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506850A Active JP6042412B2 (ja) | 2011-04-28 | 2012-04-25 | 細胞毒性ジペプチドの凍結乾燥調製物 |
Country Status (29)
| Country | Link |
|---|---|
| US (8) | US20140128462A1 (OSRAM) |
| EP (4) | EP4122482A1 (OSRAM) |
| JP (1) | JP6042412B2 (OSRAM) |
| KR (2) | KR102122416B1 (OSRAM) |
| CN (2) | CN103547279A (OSRAM) |
| AU (1) | AU2012247545B2 (OSRAM) |
| BR (2) | BR112013027584B1 (OSRAM) |
| CA (2) | CA2833500C (OSRAM) |
| CY (2) | CY1119453T1 (OSRAM) |
| DK (3) | DK3656393T3 (OSRAM) |
| ES (2) | ES2930140T3 (OSRAM) |
| FI (1) | FIC20230004I1 (OSRAM) |
| FR (1) | FR23C1000I2 (OSRAM) |
| HR (2) | HRP20171523T1 (OSRAM) |
| HU (3) | HUE060783T2 (OSRAM) |
| IL (3) | IL228889A0 (OSRAM) |
| LT (3) | LT2701720T (OSRAM) |
| LU (1) | LUC00291I2 (OSRAM) |
| MX (1) | MX345102B (OSRAM) |
| NL (1) | NL301206I2 (OSRAM) |
| NO (1) | NO2023004I1 (OSRAM) |
| PL (3) | PL2701720T3 (OSRAM) |
| PT (2) | PT2701720T (OSRAM) |
| RS (3) | RS60719B1 (OSRAM) |
| RU (1) | RU2597154C2 (OSRAM) |
| SI (2) | SI2701720T1 (OSRAM) |
| SM (3) | SMT202000447T1 (OSRAM) |
| WO (1) | WO2012146625A1 (OSRAM) |
| ZA (1) | ZA201308765B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012247545B2 (en) | 2011-04-28 | 2016-08-11 | Oncopeptides Innovation Ab | Lyophilized preparation of cytotoxic dipeptides |
| JP5827178B2 (ja) * | 2012-06-05 | 2015-12-02 | 北越紀州製紙株式会社 | セルロース多孔質体及びその製造方法 |
| DK2928463T3 (da) * | 2012-10-26 | 2020-02-24 | Oncopeptides Ab | Lyofiliserede præparater af melphalan-flufenamid |
| CN108685860B (zh) * | 2012-10-26 | 2022-04-05 | 肿瘤多肽股份公司 | 美法仑氟灭酰胺的冻干制剂 |
| GB201507903D0 (en) | 2015-05-08 | 2015-06-24 | Oncopeptides Ab | Process for preparation of nitrogen mustard derivatives |
| GB201521217D0 (en) | 2015-12-01 | 2016-01-13 | Oncopeptides Ab | Dosage regimens |
| US10369077B2 (en) * | 2017-05-31 | 2019-08-06 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using the same |
| US10507165B2 (en) | 2017-05-31 | 2019-12-17 | Adienne Pharma & Biotech Sa | Multi chamber flexible bag and methods of using same |
| IL282231B2 (en) * | 2018-10-18 | 2025-07-01 | Oncopeptides Ab | Deuterium-containing compounds |
| CN114025753A (zh) | 2019-04-03 | 2022-02-08 | 肿瘤多肽有限公司 | 用美氟芬治疗al淀粉样变性 |
| GB201905477D0 (en) * | 2019-04-17 | 2019-05-29 | Oncopeptides Ab | Novel formulations |
| WO2021053185A1 (en) | 2019-09-20 | 2021-03-25 | Oncopeptides Ab | Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma |
| EP4145995A4 (en) * | 2020-05-08 | 2024-05-22 | CJB Applied Technologies, LLC | PESTICIDE COMPOSITIONS AND RELATED METHODS |
| JP2023539154A (ja) * | 2020-08-19 | 2023-09-13 | セラクト ファーマ ジーエムビーエイチ | エトポシドトニリベート製剤 |
| US12077809B2 (en) | 2021-04-27 | 2024-09-03 | Enplas Corporation | Freeze-dried structure and producing method thereof |
| GB202109894D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| GB202109896D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| WO2023281007A1 (en) | 2021-07-08 | 2023-01-12 | Oncopeptides Ab | Melflufen for use in the treatment of multiple myeloma |
| GB202109895D0 (en) | 2021-07-08 | 2021-08-25 | Oncopeptides Ab | Novel treatments |
| KR102757193B1 (ko) * | 2021-10-19 | 2025-01-21 | 단국대학교 천안캠퍼스 산학협력단 | 피리미딘-2,4-다이온 유도체를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| GB202204171D0 (en) | 2022-03-24 | 2022-05-11 | Oncopeptides Ab | Novel formulations |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| JP3176716B2 (ja) | 1991-06-21 | 2001-06-18 | 武田薬品工業株式会社 | 溶解性が向上した難水溶性薬物組成物 |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| SE0002202D0 (sv) | 2000-06-13 | 2000-06-13 | Karolinska Innovations Ab | New peptides |
| US6992207B2 (en) * | 2000-06-13 | 2006-01-31 | Oncopeptides Ab | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
| AU2002350622B2 (en) | 2001-10-24 | 2006-09-14 | Pari Pharma Gmbh | Kit for the preparation of a pharmaceutical composition |
| BRPI0307802B8 (pt) * | 2002-02-22 | 2021-05-25 | Merck Sharp & Dohme | formulação farmacêutica compreendendo temozolomida, processo para a produção da mesma, bem como artigo fabricado contendo pó liofilizado compreendendo temozolomida |
| US6780324B2 (en) * | 2002-03-18 | 2004-08-24 | Labopharm, Inc. | Preparation of sterile stabilized nanodispersions |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
| US20050152979A1 (en) * | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| MX2007001663A (es) | 2004-08-12 | 2007-04-10 | Schering Corp | Formulacion de interferon pegilado estable. |
| KR101188691B1 (ko) * | 2004-10-29 | 2012-10-09 | 파르마 마르 에스.에이. | 엑티나시딘 및 디사카라이드를 포함하는 제제 |
| EP1674098A1 (en) * | 2004-12-23 | 2006-06-28 | Schering Aktiengesellschaft | Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| TWI360549B (en) | 2006-07-07 | 2012-03-21 | Gilead Sciences Inc | Novel pyridazine compound and use thereof |
| JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ，インコーポレーテッド | エンドキシフェンの方法および組成物 |
| CN101584669B (zh) * | 2009-06-19 | 2010-12-29 | 江苏奥赛康药业有限公司 | 美法仑冻干粉针剂 |
| WO2011078782A1 (en) * | 2009-12-22 | 2011-06-30 | Oncopeptides Ab | A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer |
| AR077384A1 (es) | 2010-07-05 | 2011-08-24 | Eriochem Sa | Una formulacion farmaceutica inyectable de melfalano. |
| HRP20201241T1 (hr) * | 2011-04-15 | 2020-11-27 | Janssen Pharmaceutica N.V. | Nanosuspenzije lijeka osušene zamrzavanjem |
| AU2012247545B2 (en) | 2011-04-28 | 2016-08-11 | Oncopeptides Innovation Ab | Lyophilized preparation of cytotoxic dipeptides |
| CN108685860B (zh) | 2012-10-26 | 2022-04-05 | 肿瘤多肽股份公司 | 美法仑氟灭酰胺的冻干制剂 |
-
2012
- 2012-04-25 AU AU2012247545A patent/AU2012247545B2/en active Active
- 2012-04-25 CN CN201280019920.7A patent/CN103547279A/zh active Pending
- 2012-04-25 SM SM20200447T patent/SMT202000447T1/it unknown
- 2012-04-25 HR HRP20171523TT patent/HRP20171523T1/hr unknown
- 2012-04-25 LT LTEP12718949.6T patent/LT2701720T/lt unknown
- 2012-04-25 CA CA2833500A patent/CA2833500C/en active Active
- 2012-04-25 EP EP22191185.2A patent/EP4122482A1/en active Pending
- 2012-04-25 RS RS20201030A patent/RS60719B1/sr unknown
- 2012-04-25 SM SM20170459T patent/SMT201700459T1/it unknown
- 2012-04-25 US US14/113,768 patent/US20140128462A1/en not_active Abandoned
- 2012-04-25 SI SI201231086T patent/SI2701720T1/sl unknown
- 2012-04-25 JP JP2014506850A patent/JP6042412B2/ja active Active
- 2012-04-25 EP EP12718949.6A patent/EP2701720B1/en active Active
- 2012-04-25 PT PT127189496T patent/PT2701720T/pt unknown
- 2012-04-25 SI SI201231829T patent/SI3228319T1/sl unknown
- 2012-04-25 KR KR1020177035122A patent/KR102122416B1/ko active Active
- 2012-04-25 EP EP17173249.8A patent/EP3228319B1/en active Active
- 2012-04-25 PL PL12718949T patent/PL2701720T3/pl unknown
- 2012-04-25 HU HUE19215699A patent/HUE060783T2/hu unknown
- 2012-04-25 RU RU2013152751/15A patent/RU2597154C2/ru active
- 2012-04-25 PT PT192156990T patent/PT3656393T/pt unknown
- 2012-04-25 LT LTEP19215699.0T patent/LT3656393T/lt unknown
- 2012-04-25 HR HRP20221355TT patent/HRP20221355T1/hr unknown
- 2012-04-25 BR BR112013027584-7A patent/BR112013027584B1/pt active IP Right Grant
- 2012-04-25 RS RS20171002A patent/RS56462B1/sr unknown
- 2012-04-25 SM SM20220450T patent/SMT202200450T1/it unknown
- 2012-04-25 MX MX2013012545A patent/MX345102B/es active IP Right Grant
- 2012-04-25 ES ES19215699T patent/ES2930140T3/es active Active
- 2012-04-25 DK DK19215699.0T patent/DK3656393T3/da active
- 2012-04-25 CN CN201810054866.9A patent/CN108096563A/zh active Pending
- 2012-04-25 WO PCT/EP2012/057577 patent/WO2012146625A1/en not_active Ceased
- 2012-04-25 RS RS20221059A patent/RS63747B1/sr unknown
- 2012-04-25 HU HUE12718949A patent/HUE037863T2/hu unknown
- 2012-04-25 DK DK17173249.8T patent/DK3228319T3/da active
- 2012-04-25 EP EP19215699.0A patent/EP3656393B1/en active Active
- 2012-04-25 BR BR122019017088-6A patent/BR122019017088B1/pt active IP Right Grant
- 2012-04-25 PL PL19215699.0T patent/PL3656393T3/pl unknown
- 2012-04-25 DK DK12718949.6T patent/DK2701720T3/en active
- 2012-04-25 KR KR1020137031096A patent/KR101808895B1/ko active Active
- 2012-04-25 ES ES12718949.6T patent/ES2642676T3/es active Active
- 2012-04-25 PL PL17173249T patent/PL3228319T3/pl unknown
- 2012-04-25 CA CA3024230A patent/CA3024230C/en active Active
-
2013
- 2013-10-15 IL IL228889A patent/IL228889A0/en active IP Right Grant
- 2013-11-21 ZA ZA2013/08765A patent/ZA201308765B/en unknown
-
2016
- 2016-08-01 US US15/225,323 patent/US10322182B2/en active Active
-
2017
- 2017-10-12 CY CY20171101070T patent/CY1119453T1/el unknown
-
2019
- 2019-03-19 IL IL265457A patent/IL265457B/en active IP Right Grant
- 2019-04-12 US US16/382,276 patent/US10543274B2/en active Active
- 2019-06-28 US US16/457,102 patent/US20200009252A1/en not_active Abandoned
- 2019-12-19 US US16/721,639 patent/US10869928B2/en active Active
-
2020
- 2020-02-03 IL IL272429A patent/IL272429B/en unknown
- 2020-07-22 US US16/935,372 patent/US11344622B2/en active Active
- 2020-08-12 CY CY20201100749T patent/CY1123242T1/el unknown
-
2022
- 2022-04-27 US US17/730,398 patent/US11896668B2/en active Active
- 2022-12-13 NL NL301206C patent/NL301206I2/nl unknown
- 2022-12-13 LU LU00291C patent/LUC00291I2/fr unknown
- 2022-12-16 LT LTPA2022529C patent/LTC2701720I2/lt unknown
-
2023
- 2023-01-04 FR FR23C1000C patent/FR23C1000I2/fr active Active
- 2023-01-16 HU HUS2300005C patent/HUS2300005I1/hu unknown
- 2023-01-16 NO NO2023004C patent/NO2023004I1/no unknown
- 2023-01-19 FI FIC20230004C patent/FIC20230004I1/fi unknown
-
2024
- 2024-07-19 US US18/400,055 patent/US20240358838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512402A5 (OSRAM) | ||
| RU2013152751A (ru) | Лиофилизированный препарат цитотоксических дипептидов | |
| KR100917809B1 (ko) | 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물 | |
| US20210008035A1 (en) | Liquid formulations of bendamustine | |
| CN102421451B (zh) | 苯达莫司汀环多糖组合物 | |
| US20220265829A1 (en) | Formulations of bendamustine | |
| KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
| CN101444510B (zh) | 含有伏立康唑的药物制剂及其制备方法 | |
| CN110876259B (zh) | 注射用组合物 | |
| JP6461945B2 (ja) | ある含有量のマイトマイシンｃを有する凍結乾燥医薬組成物を製造する方法 | |
| WO2015198257A1 (en) | Stable carfilzomib injection | |
| WO2011103150A2 (en) | Lyophilized preparations of bendamustine | |
| RU2020111026A (ru) | Препараты даптомицина | |
| KR101478779B1 (ko) | 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법 | |
| KR20140037932A (ko) | 안정화된 보리코나졸 조성물 | |
| EP2595660B1 (en) | Bendamustine anionic-catioinic cyclopolysaccharide compositions | |
| HRP20201300T1 (hr) | Liofilizirani pripravak citotoksičnih dipeptida | |
| CN117357664A (zh) | 一种甲基-β-环糊精和阿苯达唑的包合物及其制备方法 | |
| CN105769821A (zh) | 他克莫司自组装聚合物纳米粒给药系统及其制备方法 | |
| JP2016507535A5 (OSRAM) | ||
| WO2014102731A1 (en) | Novel pharmaceutical compositions of romidepsin | |
| ES2397126T3 (es) | Composición farmacéutica para la administración parenteral de un antagonista del receptor beta-adrenérgico de acción ultrarrápida | |
| US20140275122A1 (en) | Voriconazole Formulations | |
| KR20140147336A (ko) | 도세탁셀을 함유하는 액상 주사용 조성물 | |
| CN1853726A (zh) | 改善难溶药物水溶性的高聚物体系及其制备方法 |